Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com
Not everyone responds to Dupixent. For patients with moderate to severe eczema who haven’t achieved adequate control with injectable biologics, or who simply prefer an oral treatment, JAK inhibitors, specifically upadacitinib (Rinvoq) and abrocitinib (Cibinqo), represent one of the most important advances in atopic dermatitis treatment in recent years. These once daily oral medications offer rapid itch relief and strong skin clearance, making them a compelling option for the right patient. Here is everything you need to know about how they work, what the evidence shows, and who they are actually for.
What Are JAK Inhibitors for Eczema?
JAK inhibitors are targeted oral medications that block the JAK-STAT signaling pathway inside immune cells, interrupting the signals that drive inflammation in atopic dermatitis. Unlike biologics such as Dupixent, which are injectable monoclonal antibodies that block cytokines outside the cell, JAK inhibitors are small molecule drugs taken as once daily tablets that work inside the cell, interrupting inflammatory signaling at its source.
JAK stands for Janus kinase, a family of enzymes that act as internal relay switches in immune cells. When inflammatory cytokines including IL-4, IL-13, and IL-31 activate their surface receptors, JAK enzymes transmit that signal deeper into the cell, triggering the immune response that drives eczema flares. By blocking these enzymes, JAK inhibitors interrupt multiple inflammatory signals simultaneously rather than just one, which helps explain their rapid and broad clinical effect.
What Is the Difference Between Rinvoq and Cibinqo?
Both Rinvoq (upadacitinib) and Cibinqo (abrocitinib) are JAK1-selective inhibitors approved for moderate to severe atopic dermatitis, but they differ in dosing, speed of action, and trial outcomes. Upadacitinib is taken once daily at 15mg or 30mg, while abrocitinib is taken once daily at 100mg or 200mg. Both selectively target JAK1, the enzyme most closely linked to the cytokines driving eczema, rather than blocking multiple JAK enzymes indiscriminately as older, less selective JAK inhibitors did.
In practical terms, upadacitinib tends to show slightly stronger overall efficacy signals in trials, while abrocitinib has demonstrated particularly rapid itch relief in early treatment phases.
The selectivity for JAK1 is clinically important. By targeting JAK1 specifically, both drugs aim to interrupt eczema relevant inflammatory signals more precisely while reducing the risks associated with broader JAK suppression.
What Does the Clinical Evidence Show?
Both upadacitinib and abrocitinib have strong clinical trial data supporting their effectiveness for moderate to severe atopic dermatitis.
The Measure Up 1 and Measure Up 2 trials for upadacitinib, published in The Lancet, found that a significant proportion of patients achieved clear or almost clear skin within sixteen weeks, with itch reduction beginning in some patients within the first week of treatment. This rapid itch relief is one of the most clinically meaningful benefits, as itch is often the most disruptive symptom affecting sleep, mood, and daily function.
For abrocitinib, the JADE MONO trials, also published in The Lancet, showed high rates of skin clearance and itch reduction at week twelve. A head-to-head trial comparing abrocitinib against dupilumab, reviewed in the Journal of the American Academy of Dermatology, found that abrocitinib at its higher dose produced faster early itch relief in the first weeks of treatment.
Research published in the New England Journal of Medicine comparing upadacitinib directly against dupilumab found that upadacitinib at its 30mg dose produced superior skin clearance at sixteen weeks, positioning it among the most effective single agents currently available for moderate to severe atopic dermatitis in appropriate candidates.
How Do JAK Inhibitors Compare to Dupixent for Eczema?
JAK inhibitors and Dupixent target the same inflammatory pathway but at different points and through different mechanisms. Dupixent blocks IL-4 and IL-13 signalling outside the cell via injection, while JAK inhibitors block the internal relay that multiple cytokines depend on, via a once daily oral tablet.
Clinical data suggests upadacitinib at its higher dose may produce faster and, in some measures, superior skin clearance compared to dupilumab, while dupilumab has a longer real-world safety record and a well-established profile for long term use. In simple terms, JAK inhibitors may work faster and more broadly, while Dupixent offers long term safety reassurance. Neither is universally better, the right choice depends on the individual patient’s profile, preferences, and treatment history.
Why Does Oral vs Injectable Treatment Matter?
For many patients, the ability to take an oral tablet instead of a subcutaneous injection is a genuinely significant factor in treatment adherence and quality of life. According to the National Eczema Association, treatment adherence is one of the biggest challenges in managing atopic dermatitis long term, and needle phobia or injection discomfort is a real barrier for a meaningful proportion of patients.
For example, patients who travel frequently, struggle with self-injection, or simply prefer the convenience of a daily tablet often find oral therapy easier to maintain consistently. A once daily oral JAK inhibitor removes that barrier entirely for patients who are otherwise suitable candidates for systemic therapy.
What Are the Side Effects of JAK Inhibitors?
JAK inhibitors carry a class wide FDA boxed warning covering increased risks of serious cardiovascular events, blood clots, serious infections, and malignancy. Research published in JAMA Dermatology has noted that this warning originated largely from data on an older, less selective JAK inhibitor studied in a higher risk rheumatoid arthritis population, and that the clinical significance of these risks in younger, otherwise healthy eczema patients appears meaningfully different. However, the warning applies across the class and cannot be dismissed.
The British Journal of Dermatology has highlighted that careful patient selection significantly affects the risk profile of JAK inhibitor therapy. Both upadacitinib and abrocitinib require screening for latent tuberculosis before starting, regular monitoring of blood counts and lipid levels during treatment, and ongoing assessment for signs of infection. In routine practice, this typically includes baseline labs, TB screening, lipid monitoring, and ongoing infection vigilance.
Common side effects include upper respiratory tract infections, acne, and nausea, generally mild and manageable.
Who Is a Candidate for JAK Inhibitor Therapy for Eczema?
JAK inhibitors for eczema are appropriate for adults and adolescents with moderate to severe atopic dermatitis that has not responded adequately to topical prescription treatments. They are generally considered when biologic therapy is either not suitable or has not produced adequate control.
They are typically not recommended for patients over sixty-five, those with a history of cardiovascular disease, smokers, or patients with a history of certain cancers. A dermatologist will conduct a thorough risk benefit assessment before prescribing.
Is JAK Inhibitors Safe for Long Term Use in Eczema?
Long term safety data for JAK inhibitors in eczema is still accumulating compared to the longer track record of dupilumab, but extension study data reviewed in the Journal of the American Academy of Dermatology shows that efficacy is generally maintained over extended treatment periods with consistent monitoring.
Ongoing follow up, regular lab checks, and clear communication about new symptoms are essential to maintaining safety over time. Medical supervision remains a key part of therapy.
The Bottom Line
JAK inhibitors have added a powerful and genuinely important oral option for patients with moderate to severe eczema who need systemic therapy. Rinvoq and Cibinqo both produce strong clinical results, with upadacitinib in particular showing efficacy that compares favourably even against the current biologic standard.
The safety considerations are real, require proper patient selection and monitoring, and should always be discussed thoroughly with a dermatologist. But for the right patient, JAK inhibitor therapy represents one of the most effective and fast-acting targeted options currently available.
Explore More on PharmaHealths
To see how JAK inhibitors fit alongside Dupixent, Cosentyx, and Skyrizi in the full treatment picture, visit my Complete Biologics Guide on PharmaHealths.com.
Disclaimer
This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor, dermatologist, or pharmacist before starting, stopping, or changing any treatment.
References
• National Eczema Association, Patient focused guidance on eczema symptoms and treatment adherence
• The Lancet, High impact clinical trial data on JAK inhibitors
• Journal of the American Academy of Dermatology, Comparative and long-term dermatology research
• New England Journal of Medicine, Gold standard clinical trial evidence
• JAMA Dermatology, Safety data and risk interpretation
• British Journal of Dermatology, Clinical guidance on dermatology treatments
